News | Cancer

The most innovative cancer drugs take longest to reach patients, study suggests

The most innovative new cancer drugs are taking longer to pass through clinical trials, licensing and eventual appraisal by the National Institute for Health and Care Excellence, an analysis carried out by the Institute of Cancer Research has suggested.…

It’s time for comprehensive polypharmacy reviews for older people with cancer

The number of older people with cancer is growing and so is their risk of harmful polypharmacy — care for this expanding group of patients must improve.…

Working as a pharmacist on the groundbreaking new CAR-T therapy

Clinical pharmacist Jackie Chappell shares her experiences of working with CAR-T therapy, a new cell-engineering treatment for cancer.…

Combination immunotherapy for melanoma improves long-term survival rates

Patients with advanced melanoma treated with a combination of ipilimumab and nivolumab are more likely to be alive five years later than patients treated with ipilimumab alone or nivolumab alone.…

Pharmacist awarded for speaking out against approval of unproven cancer remedy

A pharmacist who successfully opposed extensive lobbying by alternative health practitioners to gain approval and reimbursement for an unproven cancer remedy has won an award from campaigning charity Sense about Science.…

First patient in Wales to begin CAR-T personalised therapy

A patient in Wales will become the first in the country to start chimeric antigen receptor T-cell therapy after other treatments for his lymphoma were unsuccessful.…

Effect of antibiotics on colorectal cancer risk varies along the gut

Oral antibiotic use is linked to an increased risk of colon cancer, but a reduced risk of rectal cancer, a study in Gut suggests.…

Nivolumab improves survival in non-small cell lung carcinoma, study results suggest

Patients treated with nivolumab for advanced non-small cell lung carcinoma had a better survival rate at five years than those who received chemotherapy, a follow-up trial has shown.…

Chemotherapy more effective than second targeted hormone therapy in resistant prostate cancer

Men with advanced prostate cancer who stop responding to targeted hormone therapy but are then treated with modern chemotherapy have better survival rates than those given a second targeted treatment, a study published in the New England Journal of Medicine has shown.…

EMA tells drug manufacturers to test for probable carcinogen

The European Medicines Agency has told drug manufacturers to test all medicines that contain chemically synthesised active substances for the presence of nitrosamines.…